Snapshot from Nov 22, 2026 at 07:00 UTC. For live data and tracking: View Live
Entity

Canada — Canada s Drug Agency

Tracked across 4 events · 25 articles · First seen Jul 06, 2026 · Last active Sep 17, 2026

Sentiment
14
Attention
4
Events
4
Relationships
0
Live sentiment trends, attention charts, and prominence tracking available on the Ergen Dashboard
2 0
Regulatory
Impact: Issued updated recommendation to fund lecanemab for early-stage Alzheimer's, reversing earlier decision.
Jul 16, 2026 · 7 articles
4 50
Regulatory
Impact: The agency issued the final positive recommendation, a key regulatory step that facilitates public reimbursement of Leqembi in Canada.
Sep 01, 2026 · 6 articles
3 0
Business
Impact: CDA-AMC issued a positive reimbursement recommendation for ALYFTREK in December 2025, which preceded the LOI.
Jul 06, 2026 · 6 articles
1 5
Business
Boehringer Ingelheim announced the launch of PED Essentials, a free online e-learning hub designed to help patient organizations generate, analyze and share high-quality patient experience data (PED). The platform was co-created with patients and subject…
Impact: Canada — Canada s Drug Agency is cited alongside NICE as increasingly using patient evidence in HTA and reimbursement decisions, supporting the rationale for the PED Essentials hub.
Sep 17, 2026 · 6 articles
ERGEN INTELLIGENCE
Track Canada — Canada s Drug Agency live

Set up alerts, explore relationships, view sentiment trends, and monitor how events impact this entity in real time.

Open Dashboard

About Ergen

Ergen is a news intelligence platform that converts raw news articles into structured data. It tracks events, entities, and the relationships between them, with sentiment and attention metrics derived from thousands of articles. Pages on this site are daily static snapshots from the platform's live database. For real-time tracking, search, and alerts, the full dashboard is at app.ergen.ai.